Axel Merseburger takes us through the studies that caught his attention at the 2020 Genitourinary Cancers Symposium (ASCO GU 2020), including the NIMBUS trial and first-in-human study of the HIF-2α inhibitor MK-6482 (3:24).
16-02-2020 | ASCO GU 2020 | Conference coverage | Video